Ambu A/S (AMBU B.CO) Stock Price

Ambu A/S Price

OMX·CLOSED
73.40DKK+0.30 (+0.41 %)
Market closed

Over the last 10 years Ambu A/S grew revenue by 12.3% annually, reaching 6.04 B DKK. Earnings per share have grown at 14.0% per year over the last 10 years. For Ambu A/S, the net margin of 10.1% is up versus 6.2% a few years ago. At today's price the dividend yield works out to roughly 0.56%. The payout ratio is around 18% of earnings. The consensus 12-month price target for Ambu A/S is 122.40 DKK, about 66.8% above where the stock trades today. Of 12 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.

Ambu A/S stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Ambu A/S over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ambu A/S stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ambu A/S's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ambu A/S Stock Price History
DateAmbu A/S Price
8/7/202673.40 DKK
8/6/202673.10 DKK
8/5/202673.25 DKK
8/4/202673.75 DKK
7/31/202672.35 DKK
7/30/202672.70 DKK
7/29/202672.20 DKK
7/28/202670.55 DKK
7/27/202670.10 DKK
7/24/202668.15 DKK
7/23/202667.10 DKK
7/22/202669.25 DKK
7/21/202669.65 DKK
7/20/202671.25 DKK
7/17/202669.75 DKK
7/16/202670.65 DKK
7/15/202669.20 DKK
7/14/202668.55 DKK
7/13/202669.05 DKK
7/10/202668.60 DKK
7/9/202667.75 DKK
7/8/202667.45 DKK
7/7/202668.00 DKK
7/6/202666.75 DKK
7/3/202665.85 DKK
7/2/202666.50 DKK
7/1/202664.20 DKK
6/30/202661.00 DKK
6/29/202661.40 DKK
6/26/202660.95 DKK
6/25/202661.00 DKK
6/24/202658.90 DKK
6/23/202662.65 DKK
6/22/202663.10 DKK
6/19/202663.65 DKK
6/18/202662.00 DKK
6/17/202662.50 DKK
6/16/202663.10 DKK
6/15/202664.25 DKK
6/12/202663.35 DKK
6/11/202663.65 DKK
6/10/202664.25 DKK
6/9/202665.00 DKK
6/8/202664.40 DKK
6/4/202666.00 DKK
6/3/202663.95 DKK
6/2/202664.55 DKK
6/1/202665.65 DKK
5/29/202667.40 DKK
5/28/202665.60 DKK
5/27/202666.80 DKK
5/26/202666.70 DKK
5/22/202668.15 DKK
5/21/202667.55 DKK
5/20/202666.35 DKK
5/19/202665.45 DKK
5/18/202664.20 DKK
5/13/202662.45 DKK
5/12/202662.50 DKK
5/11/202661.85 DKK
5/8/202662.40 DKK
5/7/202662.55 DKK
5/6/202662.40 DKK
5/5/202664.80 DKK
5/4/202665.65 DKK
5/1/202665.45 DKK
4/30/202663.05 DKK
4/29/202661.70 DKK
4/28/202664.80 DKK
4/27/202664.90 DKK
4/24/202665.05 DKK
4/23/202666.15 DKK
4/22/202668.05 DKK
4/21/202669.35 DKK
4/20/202670.00 DKK
4/17/202670.80 DKK
4/16/202667.75 DKK
4/15/202667.80 DKK
4/14/202666.85 DKK
4/13/202665.55 DKK
4/10/202665.40 DKK
4/9/202664.35 DKK
4/8/202665.70 DKK
4/7/202664.50 DKK
4/1/202669.05 DKK
3/31/202668.40 DKK
3/30/202667.75 DKK
3/27/202667.65 DKK
3/26/202669.25 DKK
3/25/202668.10 DKK
3/24/202667.60 DKK
3/20/202667.40 DKK
3/19/202667.95 DKK
3/18/202669.90 DKK
3/17/202670.95 DKK
3/16/202671.80 DKK
3/13/202671.90 DKK
3/12/202671.45 DKK
3/11/202673.05 DKK
3/10/202675.25 DKK
3/9/202674.50 DKK
3/6/202675.65 DKK
3/5/202677.05 DKK
3/4/202677.75 DKK
3/3/202674.60 DKK
3/2/202678.90 DKK
2/27/202679.50 DKK
2/26/202679.70 DKK
2/25/202678.35 DKK
2/24/202678.45 DKK
2/23/202678.90 DKK
2/20/202681.45 DKK
2/19/202680.10 DKK
2/18/202681.05 DKK
2/17/202681.60 DKK
2/16/202681.75 DKK
2/13/202682.40 DKK
2/12/202683.00 DKK
2/11/202682.60 DKK
2/10/202686.45 DKK
2/9/202686.35 DKK
2/6/202687.90 DKK
2/5/202684.05 DKK
2/4/202687.85 DKK
2/3/202683.20 DKK
2/2/202684.70 DKK
1/30/202685.10 DKK
1/29/202685.00 DKK
1/28/202685.40 DKK
1/27/202686.05 DKK
1/26/202686.90 DKK
1/23/202687.05 DKK
1/22/202688.55 DKK
1/21/202686.40 DKK
1/20/202687.55 DKK
1/19/202685.25 DKK
1/16/202691.25 DKK
1/15/202690.15 DKK
1/14/202691.00 DKK
1/13/202691.00 DKK
1/12/202689.40 DKK
1/9/202688.75 DKK
1/8/202688.50 DKK
1/7/202687.85 DKK
1/6/202690.25 DKK
1/5/202687.50 DKK
1/2/202686.25 DKK
12/30/202588.00 DKK
12/29/202588.60 DKK
12/23/202587.75 DKK
12/22/202587.85 DKK
12/19/202587.75 DKK
12/18/202586.95 DKK
12/17/202587.05 DKK
12/16/202587.25 DKK
12/15/202587.50 DKK
12/12/202586.85 DKK
12/11/202585.60 DKK
12/10/202585.05 DKK
12/9/202584.75 DKK
12/8/202585.95 DKK
12/5/202587.25 DKK
12/4/202586.95 DKK
12/3/202587.00 DKK
12/2/202586.40 DKK
12/1/202586.00 DKK
11/28/202587.30 DKK
11/27/202588.00 DKK
11/26/202587.95 DKK
11/25/202588.25 DKK
11/24/202588.15 DKK
11/21/202587.95 DKK
11/20/202588.10 DKK
11/19/202587.15 DKK
11/18/202584.60 DKK
11/17/202585.35 DKK
11/14/202585.40 DKK
11/13/202585.85 DKK
11/12/202585.65 DKK
11/11/202584.30 DKK
11/10/202582.45 DKK
11/7/202581.75 DKK
11/6/202583.15 DKK
11/5/202583.15 DKK
11/4/202598.75 DKK
11/3/202599.25 DKK
10/31/2025100.70 DKK
10/30/2025102.30 DKK
10/29/2025104.10 DKK
10/28/2025104.80 DKK
10/27/2025106.20 DKK
10/24/2025107.70 DKK
10/23/2025107.10 DKK
10/22/2025106.30 DKK
10/21/2025105.80 DKK
10/20/2025105.30 DKK
10/17/2025105.30 DKK
10/16/2025105.40 DKK
10/15/2025101.60 DKK
10/14/2025100.40 DKK
10/13/2025101.70 DKK
10/10/2025103.10 DKK
10/9/2025104.80 DKK
10/8/2025106.50 DKK
10/7/2025107.10 DKK
10/6/2025106.60 DKK
10/3/2025106.90 DKK
10/2/2025103.40 DKK
10/1/2025101.20 DKK
9/30/202592.60 DKK
9/29/202594.85 DKK
9/26/202593.20 DKK
9/25/202591.05 DKK
9/24/202597.15 DKK
9/23/202597.20 DKK
9/22/202596.85 DKK
9/19/202598.45 DKK
9/18/202599.00 DKK
9/17/202597.20 DKK
9/16/202598.60 DKK
9/15/202597.35 DKK
9/12/202596.80 DKK
9/11/202596.20 DKK
9/10/202595.70 DKK
9/9/202598.80 DKK
9/8/202597.95 DKK
9/5/202596.75 DKK
9/4/202595.05 DKK
9/3/202595.65 DKK
9/2/202595.60 DKK
9/1/202596.30 DKK
8/29/202596.25 DKK
8/28/202597.40 DKK
8/27/202597.80 DKK
8/26/202598.20 DKK
8/25/2025101.20 DKK
8/22/2025101.80 DKK
8/21/202595.50 DKK
8/20/202595.35 DKK
8/19/202594.95 DKK
8/18/202593.95 DKK
8/15/202591.95 DKK
8/14/202590.70 DKK
8/13/202592.10 DKK
8/12/202591.50 DKK
Access this data via the Eulerpool API
Get Free API Key

Ambu A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.78 B DKK
302.00 M DKK
168.00 M DKK
Jan 1, 2024
5.39 B DKK
645.00 M DKK
235.00 M DKK
Jan 1, 2025
6.04 B DKK
784.00 M DKK
609.00 M DKK
Jan 1, 2026 (e)
6.58 B DKK
892.07 M DKK
599.15 M DKK
Jan 1, 2027 (e)
7.36 B DKK
1.19 B DKK
794.82 M DKK
Jan 1, 2028 (e)
8.26 B DKK
1.51 B DKK
1.01 B DKK
Jan 1, 2029 (e)
9.10 B DKK
1.76 B DKK
1.26 B DKK
Jan 1, 2030 (e)
10.22 B DKK
2.10 B DKK
1.49 B DKK

Ambu A/S Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 3:06 PM
 
REVENUEB DKK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB DKK
EBITB DKK
EBIT MARGIN%
NET INCOMEB DKK
NET INCOME GROWTH%
DIV.DKK
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
2.082.362.612.823.574.014.444.785.396.046.587.368.269.1010.2211.31
10.3213.0010.668.2126.4912.5010.747.4512.9011.989.0611.7912.2810.1612.2710.61
53.9356.5259.3658.0562.0162.3758.1056.8259.3860.1860.1860.1860.1860.1860.1860.18
1.121.331.551.642.212.502.582.713.203.633.964.434.975.486.156.80
0.360.450.560.480.430.340.150.300.650.780.891.191.511.762.10–
17.0819.1121.6017.0212.008.473.386.3211.9612.9913.5516.1018.2219.2920.57–
0.250.300.340.320.240.250.090.170.240.610.600.791.011.261.491.64
64.4720.4011.96-5.93-23.972.49-62.3580.6539.88159.15-1.6432.5527.3324.2318.2310.71
1.551.850.400.380.290.290.29–0.380.410.410.410.41–––
63.1619.35-78.38-5.00-23.68––––7.89––––––
243.92242.97247.70247.46246.56251.77253.99260.48266.33266.48266.48266.48266.48266.48266.48266.48
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ambu A/S generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ambu A/S retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ambu A/S's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ambu A/S has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ambu A/S's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ambu A/S stock margins

The Ambu A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ambu A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ambu A/S.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
62.37 %
8.47 %
6.15 %
Jan 1, 2022
58.10 %
3.38 %
2.09 %
Jan 1, 2023
56.82 %
6.32 %
3.52 %
Jan 1, 2024
59.38 %
11.96 %
4.36 %
Jan 1, 2025
60.18 %
12.99 %
10.09 %
Jan 1, 2026 (e)
60.18 %
13.55 %
9.10 %
Jan 1, 2027 (e)
60.18 %
16.10 %
10.80 %
Jan 1, 2028 (e)
60.18 %
18.22 %
12.24 %

Ambu A/S Stock Revenue, EBIT, Earnings per Share

The Ambu A/S earnings per share therefore indicates how much revenue Ambu A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
15.94 DKK
1.35 DKK
0.98 DKK
Jan 1, 2022
17.50 DKK
0.59 DKK
0.37 DKK
Jan 1, 2023
18.33 DKK
1.16 DKK
0.64 DKK
Jan 1, 2024
20.24 DKK
2.42 DKK
0.88 DKK
Jan 1, 2025
22.65 DKK
2.94 DKK
2.29 DKK
Jan 1, 2026 (e)
28.02 DKK
3.35 DKK
2.55 DKK
Jan 1, 2027 (e)
31.32 DKK
4.45 DKK
3.38 DKK
Jan 1, 2028 (e)
35.17 DKK
5.65 DKK
4.30 DKK

Ambu A/S business model & stock analysis

Ambu A/S is a Danish company that manufactures and distributes medical products. The company was founded in 1937 and initially specialized in the production of electrodes for medical devices. Over time, Ambu has expanded its business to various medical products. Ambu's business model is based on the development and marketing of innovative medical products. The company places great value on research and development, investing a significant portion of its revenue into this area each year. Ambu operates seven research and development facilities worldwide and employs over 700 staff in this area. Ambu operates globally in three divisions: Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. In the Anaesthesia division, the company offers products such as anaesthesia masks, ventilation bags, and disposable laryngoscopes. These products are used by anaesthesiologists and intensive care nurses to intubate and ventilate patients. In the Patient Monitoring & Diagnostics division, the company offers products such as electrodes, probes, and other accessories for monitoring vital parameters. Ambu's patient monitoring systems enable the monitoring of patients in hospitals, clinics, and other medical facilities. In the Emergency Care division, Ambu offers products such as defibrillators, ventilation devices, and portable ventilation bags that are used by emergency services, paramedics, and other emergency medical services. Ambu's products are designed to provide life-saving assistance in emergency situations. Ambu is a leading provider of disposable products in the medical industry. The company believes that disposable products are the best choice for patient safety and hygiene. Disposable products minimize the risk of infection and contamination while improving hygiene in medical facilities. Ambu is committed to minimizing the environmental impact of its products. The company uses environmentally friendly materials in the manufacture of its products and ensures that its products can be safely disposed of after use. Ambu strives to promote sustainability in all aspects of its business. In summary, Ambu A/S is a leading provider of medical products that focuses on the development and marketing of innovative medical products. The company operates in three divisions and offers a wide range of products tailored to the needs of patients and medical professionals. Ambu is also committed to minimizing the environmental impact of its products and promoting sustainability.

Ambu A/S SWOT Analysis

Strengths

Ambu A/S has several strengths that contribute to its competitive advantage:

  • Strong brand reputation and recognition in the medical device industry.
  • Innovative and technologically advanced products that meet customer needs.
  • Wide range of product offerings catering to different medical specialties.
  • Global distribution network providing access to diverse markets.
  • Good financial performance and steady revenue growth.

Despite its strengths, Ambu A/S also faces certain weaknesses that need consideration:

  • Relatively high product prices compared to competitors.
  • Dependency on key suppliers for critical components.
  • Limited presence in emerging markets.
  • Regulatory and compliance challenges in different regions.

Ambu A/S can leverage the following opportunities to drive growth:

  • Increasing demand for minimally invasive medical devices.
  • Expanding into emerging markets with growing healthcare infrastructure.
  • Partnerships and collaborations with healthcare institutions and professionals.
  • Advancements in technology and digital healthcare solutions.
  • Acquisition or licensing of complementary products or technologies.

Ambu A/S should be aware of the following threats that could impact its business:

  • Intense competition from both established and emerging players.
  • Rapidly changing regulatory landscape affecting product approvals.
  • Challenges related to intellectual property protection.
  • Geopolitical and economic uncertainties impacting global business operations.
  • Potential disruptions in the supply chain due to unforeseen events.

Weaknesses

Despite its strengths, Ambu A/S also faces certain weaknesses that need consideration:

  • Relatively high product prices compared to competitors.
  • Dependency on key suppliers for critical components.
  • Limited presence in emerging markets.
  • Regulatory and compliance challenges in different regions.

Ambu A/S can leverage the following opportunities to drive growth:

  • Increasing demand for minimally invasive medical devices.
  • Expanding into emerging markets with growing healthcare infrastructure.
  • Partnerships and collaborations with healthcare institutions and professionals.
  • Advancements in technology and digital healthcare solutions.
  • Acquisition or licensing of complementary products or technologies.

Ambu A/S should be aware of the following threats that could impact its business:

  • Intense competition from both established and emerging players.
  • Rapidly changing regulatory landscape affecting product approvals.
  • Challenges related to intellectual property protection.
  • Geopolitical and economic uncertainties impacting global business operations.
  • Potential disruptions in the supply chain due to unforeseen events.

Opportunities

Ambu A/S can leverage the following opportunities to drive growth:

  • Increasing demand for minimally invasive medical devices.
  • Expanding into emerging markets with growing healthcare infrastructure.
  • Partnerships and collaborations with healthcare institutions and professionals.
  • Advancements in technology and digital healthcare solutions.
  • Acquisition or licensing of complementary products or technologies.

Ambu A/S should be aware of the following threats that could impact its business:

  • Intense competition from both established and emerging players.
  • Rapidly changing regulatory landscape affecting product approvals.
  • Challenges related to intellectual property protection.
  • Geopolitical and economic uncertainties impacting global business operations.
  • Potential disruptions in the supply chain due to unforeseen events.

Threats

Ambu A/S should be aware of the following threats that could impact its business:

  • Intense competition from both established and emerging players.
  • Rapidly changing regulatory landscape affecting product approvals.
  • Challenges related to intellectual property protection.
  • Geopolitical and economic uncertainties impacting global business operations.
  • Potential disruptions in the supply chain due to unforeseen events.

Ambu A/S Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ambu A/S historical P/E ratio, EBIT multiple, and P/S ratio

Ambu A/S annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ambu A/S shares outstanding

The number of shares of Ambu A/S was 266.48 M in 2025. This indicates how many shares Ambu A/S is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
251.77 M Stocks
Jan 1, 2022
253.99 M Stocks
Jan 1, 2023
260.48 M Stocks
Jan 1, 2024
266.33 M Stocks
Jan 1, 2025
266.48 M Stocks
Jan 1, 2026 (e)
266.48 M Stocks
Jan 1, 2027 (e)
266.48 M Stocks
Jan 1, 2028 (e)
266.48 M Stocks

Ambu A/S stock splits

In Ambu A/S's history, there have been no stock splits.

Ambu A/S Dividend History

33 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20250.41DKK↑ 7.9%1×
Dec 4, 20250.41DKK↑ 7.9%1/1
20240.38DKK↑ 31.0%1×
20220.29DKK 0.0%—
20210.29DKK 0.0%1×
20200.29DKK↓ 23.7%1×
20190.38DKK↓ 5.0%1×
20180.40DKK↓ 78.4%1×
20171.85DKK↑ 19.4%1×
20161.55DKK↑ 63.2%1×
20150.95DKK↓ 74.7%1×

Ambu A/S dividend history and estimates

In 2025, Ambu A/S paid a dividend amounting to 0.41 DKK. Dividend means that Ambu A/S distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
0.29 DKK
0.00 DKK
Jan 1, 2021
0.29 DKK
0.00 DKK
Jan 1, 2022
0.29 DKK
0.00 DKK
Jan 1, 2024 (e)
0.00 DKK
0.38 DKK
Jan 1, 2025
0.41 DKK
0.00 DKK
Jan 1, 2026
0.41 DKK
0.00 DKK
Jan 1, 2027 (e)
0.00 DKK
0.41 DKK
Jan 1, 2028 (e)
0.00 DKK
0.41 DKK

Ambu A/S dividend payout ratio

In 2025, Ambu A/S had a payout ratio of 17.94%. The payout ratio indicates the percentage of the company's profits that Ambu A/S distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
29.56 %
Jan 1, 2022
30.19 %
Jan 1, 2023
30.40 %
Jan 1, 2024
43.06 %
Jan 1, 2025
17.94 %
Jan 1, 2026 (e)
16.08 %
Jan 1, 2027 (e)
12.18 %
Jan 1, 2028 (e)
9.62 %

Current Ambu A/S forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (9)
Hold
25.00 % (3)
Sell
0.00 % (0)
12M Price Target
122.40
Last Price
72.85
Currency
DKK
12M Return Potential
68.02 %
LTM Return
0 %

Ambu A/S Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/1/20240.31DKK-1.33 BDKK-2024 Q2
2/5/20240.26DKK-1.24 BDKK-2024 Q1

EESG©

Eulerpool ESG Scorecard© for the Ambu A/S stock

68/100
68
Environment
64
Social
73
Governance
E

Environment

20
Scope 1 - Direct Emissions3,369
Scope 2 - Indirect emissions from purchased energy23,173
Scope 3 - Indirect emissions within the value chain190,388
Total CO₂ emissions26,541
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees63
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ambu A/S shareholder structure

% Name
5.84842%
Schroder Investment Management North America Inc.
Schroder Investment Management North America Inc.
5.04182%
Capital Research Global Investors
Capital Research Global Investors
2.72076%
Allianz Global Investors GmbH
Allianz Global Investors GmbH
2.11837%
Artisan Partners Limited Partnership
Artisan Partners Limited Partnership
1.84028%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.09036%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Ambu A/S Executives and Management Board

17 members · avg. age 51 · 35 % women

BJ

Ms. Britt Meelby Jensen (47)

Chief Executive Officer, Member of the Executive Board · since 2019

22.90 M DKK

Management

HB

Mr. Henrik Bender

Chief Financial Officer, Member of the Executive Board

7.97 M DKK
SB

Mr. Steven Block (60)

President of Ambu USA

–
GM

Ms. Graziela Malucelli (51)

Chief Operations Officer

–
SH

Ms. Sanne Hjordrup (47)

Chief People & Culture Officer

–
FM

Mr. Finn Mohring (59)

Chief Technology Officer, R&D · since 2023

–
BR

Mr. Bassel Rifai (41)

President of EMEA & APAC Sales, Chief Marketing Officer

–

Board of Directors

JJ

Mr. Joergen Jensen (56)

Independent Chairman of the Board

1.52 M DKK
SP

Ms. Shacey Petrovic (51)

Independent Vice Chairman of the Board · since 2022

999,000.00 DKK
MP

Mr. Michael Del Prado (61)

Independent Director

842,000.00 DKK
SL

Ms. Susanne Larsson (56)

Independent Director

840,000.00 DKK
SH

Mr. Simon Hoffmann (46)

Independent Director

467,000.00 DKK
JF

Mr. Jesper Mads Bartroff Frederiksen (49)

Director, Employee Representative

350,000.00 DKK

Frequently asked questions about Ambu A/S

Ambu A/S is primarily present in various countries and regions worldwide. With its global presence, Ambu A/S operates in several key markets, including Europe, North America, and Asia-Pacific. The company's products and services cater to customers across numerous geographies, facilitating access to innovative medical solutions. Ambu A/S leverages its extensive international network to deliver high-quality healthcare devices and support healthcare professionals in improving patient outcomes. With a strong presence in multiple countries and regions, Ambu A/S demonstrates its commitment to serving customers and driving advancements in medical technology on a global scale.

Ambu A/S is a Danish company specializing in the development, manufacturing, and marketing of medical devices. Its business model revolves around providing innovative solutions for healthcare professionals, with a focus on respiratory care and patient monitoring. Ambu offers a wide range of high-quality products, such as flexible endoscopes, anesthesia devices, and single-use consumables. By combining expertise in engineering, medical science, and digital technology, Ambu aims to improve patient care, enhance clinical efficiency, and reduce healthcare costs. With a commitment to continuous research and development, Ambu strives to provide medical professionals with state-of-the-art solutions that prioritize patient safety and comfort.

Ambu A/S is primarily active in the medical device industry.

The main competitors of Ambu A/S in the market include Medtronic, Philips Healthcare, and Smiths Medical.

Ambu A/S is a Danish company specializing in medical devices and equipment. Established in 1937, Ambu has a rich history and a strong background in the healthcare industry. The company's focus lies in developing innovative solutions for diagnostics and patient monitoring, including products such as endoscopes and anesthesia masks. Ambu has a global presence, with operations in more than 120 countries and partnerships with various healthcare providers. Over the years, Ambu has earned a reputation for its high-quality products and commitment to improving patient care. With its extensive experience and expertise, Ambu A/S continues to be a leading player in the medical technology sector.

Some significant milestones achieved by Ambu A/S include continuous innovation in the field of single-use endoscopy, leading to the development of Ambu® aScope™, an innovative solution for visualizing the airways. The company has also achieved global recognition for their breakthrough product, Ambu® BlueSensor™ electrodes, which are used in monitoring patient vital signs during surgery. Ambu A/S has expanded its presence across multiple countries, establishing a strong global footprint. Moreover, the company has received several prestigious awards, including the Red Dot Design Award and the Medical Design Excellence Award, affirming their commitment to providing high-quality medical devices.

Ambu A/S represents a corporate philosophy based on certain key values. These values include innovation, quality, and a focus on improving patient outcomes. Ambu aims to provide innovative medical solutions that enhance the efficiency and safety of medical procedures. The company strives to maintain a high standard of quality in its product offerings, ensuring reliability and accuracy for healthcare professionals. Ambu's mission is to enable medical professionals to make better decisions and improve patient care. With a commitment to these values, Ambu A/S aims to be a trusted leader in the medical device industry.

Analysts currently set an average price target of 121.52 DKK for the Ambu A/S stock (median: 122.40 DKK), implying +66.8 % versus the latest price. The consensus is based on 12 analyst ratings.

Ambu A/S Analyst Price Targets 2026

12 analysts currently rate the Ambu A/S stock: 9 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Ambu A/S to generate revenue of 6.58 B DKK and earnings per share of 2.25 DKK.

Ambu A/S Analyst Price Targets 2026

Converted at the current exchange rate, the Ambu A/S share trades at 9.83 EUR (73.40 DKK).

The Ambu A/S share (AMBU B.CO) is listed on 7 stock exchanges, including: Frankfurt (547A.F), München (547A.MU), Düsseldorf (547A.DU), London (0MJF.L).

Ambu A/S is a Danish company specializing in the development, production, and marketing of medical products. It was founded in 1937 and is headquartered in Copenhagen. The company has branches in various parts of the world. Ambu is focused on three main business areas: anesthesia, patient monitoring, and diagnostics. In the anesthesia field, Ambu offers devices and instruments used in anesthesia procedures, including laryngeal tubes, masks, and ventilator bags. In patient monitoring, Ambu provides a range of products, including electrodes for measuring brain activity, accessories for EKG and pulse oximetry, and non-invasive blood pressure monitors. In the diagnostics field, Ambu offers endoscopes used in the examination of body cavities and internal organs. The company follows a business model focused on innovation and technological advancement. It invests a significant portion of its revenue in research and development to bring new and improved products to the market that meet customer requirements and contribute to improving medical care. Ambu also emphasizes high product quality and safety throughout the value chain, from development and production to marketing and customer support. In addition to product sales, Ambu provides comprehensive support and training opportunities to its customers, building strong long-term relationships. Overall, Ambu is a leading company in the field of medical technology, dedicated to improving medical care through innovative and effective products.

The expected revenue of Ambu A/S is 6.58 B DKK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Ambu A/S is 599.15 M DKK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Ambu A/S is currently 32.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ambu A/S stock.

The price-to-sales ratio (P/S) of Ambu A/S is currently 2.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ambu A/S stock.

The Eulerpool Quality Score for Ambu A/S is 7/10.

The ISIN of Ambu A/S is DK0060946788. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Ambu A/S is A2JAHY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Ambu A/S is AMBU B.CO. The ticker symbol is used to trade Ambu A/S shares on the stock exchange.

Over the past 12 months, Ambu A/S paid a dividend of 0.41 DKK . This corresponds to a dividend yield of about 0.56 %. For the coming 12 months, Ambu A/S is expected to pay a dividend of 0.41 DKK.

The current dividend yield of Ambu A/S is 0.56 %.

Ambu A/S pays a dividend, distributed in the months of , , , .

Ambu A/S paid dividends every year for the past 2 years.

For the upcoming 12 months, dividends amounting to 0.41 DKK are expected. This corresponds to a dividend yield of 0.57 %.

Ambu A/S is assigned to the 'Health' sector.

To receive the latest dividend of Ambu A/S from amounting to 0.41 DKK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Ambu A/S are distributed in DKK.

All fundamentals and in-depth analysis of Ambu A/S

Our stock analysis for Ambu A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ambu A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Ambu A/S Stock
Ambu A/S Revenue→
Ambu A/S Stock
Ambu A/S Net Income→
Ambu A/S Stock
Ambu A/S P/E→
Ambu A/S Stock
Ambu A/S P/S→
Ambu A/S Stock
Ambu A/S EBIT→
Ambu A/S Stock
Ambu A/S Dividend→
Ambu A/S Stock
Ambu A/S Directors Dealings→
Ambu A/S Stock
Ambu A/S Stocks→
Ambu A/S Stock
Ambu A/S Market capitalization→
Ambu A/S Stock
Ambu A/S Debt→
Ambu A/S Stock
Ambu A/S Liabilities→
Ambu A/S Stock
Ambu A/S Equity→
Ambu A/S Stock
Ambu A/S AAQS→
Ambu A/S Stock
Ambu A/S Employees→
Ambu A/S Stock
Ambu A/S ROE→
Ambu A/S Stock
Ambu A/S ROA→
Ambu A/S Stock
Ambu A/S ROCE→
Ambu A/S Stock
Ambu A/S News→
Ambu A/S Stock
Ambu A/S Analyst Price Targets→

Health Stocks

AmCad BioMedAmbea AB (publ)Amed CoAmbalal Sarabhai EnterprisesAmerican Diversified HoldingsAmarin CorporationAmerican FilmsAmarantus Bioscience HoldingsAmerican GreenAlzinovaAmerican Health ProtectionAlzeCure PharmaAll Stocks A–Z →